Natera, Inc. $NTRA Shares Sold by Thematics Asset Management

Key Points

• Thematics Asset Management has reduced its stake in Natera, Inc. by 36.3%, now holding 31,426 shares valued at approximately $4.44 million.
• Natera reported a revenue of $546.60 million for the most recent quarter, exceeding analyst estimates, despite EPS falling short of expectations.
• Analysts have mixed ratings on Natera's stock, with target prices ranging from $170 to $255, reflecting a consensus "Buy" rating overall.

Thematics Asset Management lessened its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 36.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,426 shares of the medical research company's stock after selling 17,907 shares during the quarter. Thematics Asset Management's holdings in Natera were worth $4,444,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Natera by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock worth $1,752,611,000 after acquiring an additional 77,357 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares during the period. JPMorgan Chase & Co. lifted its position in Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after purchasing an additional 660,538 shares in the last quarter. Invesco Ltd. lifted its position in Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock valued at $287,908,000 after purchasing an additional 245,719 shares in the last quarter. Finally, Lord Abbett & CO. LLC grew its holdings in Natera by 5.6% during the first quarter. Lord Abbett & CO. LLC now owns 1,521,300 shares of the medical research company's stock valued at $215,127,000 after purchasing an additional 80,865 shares during the period. Institutional investors own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Royal Bank Of Canada boosted their price objective on Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Piper Sandler reiterated an "overweight" rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. UBS Group lifted their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Finally, Cowen reiterated a "buy" rating on shares of Natera in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the stock. According to MarketBeat.com, Natera presently has a consensus rating of "Buy" and an average price target of $193.19.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 2,496 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $133.17, for a total value of $332,392.32. Following the completion of the sale, the director directly owned 5,763 shares of the company's stock, valued at $767,458.71. This represents a 30.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John Fesko sold 678 shares of Natera stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the completion of the transaction, the insider owned 152,747 shares in the company, valued at $23,746,048.62. This represents a 0.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 58,705 shares of company stock valued at $8,743,776 in the last ninety days. Corporate insiders own 5.63% of the company's stock.

Natera Price Performance

Shares of NASDAQ NTRA traded up $4.84 during midday trading on Thursday, reaching $167.88. 842,647 shares of the stock traded hands, compared to its average volume of 1,500,739. The company's 50 day moving average is $154.54 and its 200 day moving average is $154.08. Natera, Inc. has a one year low of $110.57 and a one year high of $183.00. The stock has a market capitalization of $23.04 billion, a PE ratio of -87.90 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company's revenue was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.